SELLAS Life Sciences Group Inc. (NASDAQ:SLS) skyrocketed to a 52-week high on Tuesday with a session volume of a massive 57.567 million compared to an average volume of 6.897 million, according to Benzinga Pro data. The company released positive topline results from its pivotal randomized Phase 3 REGAL trial evaluating galinpepimut-S (GPS), an immunotherapeutic cancer vaccine for acute myeloid leukemia...
SELLAS Stock Triples on Cancer Vaccine Cutting Death Risk by 41% in Pivotal Leukemia Trial,
SELLAS Life Sciences Group Inc. (NASDAQ:SLS) skyrocketed to a 52-week high on Tuesday with a session volume of a massive...
By Dhallo News · November 17, 2026 at 8:39 PM IST
Have feedback on this article?Report error or suggestion
